MIRM
Mirum Pharmaceuticals, Inc. NASDAQ$105.79
Mkt Cap $5.3B
52w Low $40.00
93.3% of range
52w High $110.48
50d MA $93.83
200d MA $79.66
P/E (TTM)
-205.4x
EV/EBITDA
231.8x
P/B
15.4x
Debt/Equity
1.0x
ROE
-7.4%
P/FCF
72.3x
RSI (14)
—
ATR (14)
—
Beta
0.52
50d MA
$93.83
200d MA
$79.66
Avg Volume
812.9K
About
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia diseas…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | 1M% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 25, 2026 | AMC | 0.02 | -0.11 | -650.0% | 108.62 | -11.1% | -15.1% | -15.0% | -17.1% | -19.2% | -14.3% | -18.6% | — |
| Nov 4, 2025 | AMC | -0.10 | 0.05 | +150.0% | 70.97 | +3.5% | -1.2% | -4.6% | -4.0% | -1.8% | +0.5% | +0.8% | — |
| Aug 6, 2025 | AMC | -0.31 | -0.12 | +61.3% | 53.39 | +3.5% | +12.0% | +12.3% | +23.4% | +21.2% | +22.0% | +42.5% | — |
| May 7, 2025 | AMC | -0.39 | -0.30 | +23.1% | 41.22 | -3.0% | +9.8% | +7.4% | +10.6% | +9.8% | +7.7% | +12.5% | — |
| Feb 26, 2025 | AMC | -0.27 | -0.49 | -81.5% | 50.52 | -3.0% | -7.0% | -5.8% | -9.0% | -10.5% | -11.6% | -9.0% | — |
| Nov 12, 2024 | AMC | -0.45 | -0.30 | +33.3% | 42.28 | +2.1% | +3.9% | +9.4% | +5.3% | -2.0% | -0.4% | +0.0% | — |
| Aug 7, 2024 | AMC | -0.48 | -0.52 | -8.3% | 38.96 | +0.0% | +2.3% | +2.7% | +14.8% | +5.5% | +6.5% | +5.5% | — |
| May 8, 2024 | AMC | -0.40 | -0.54 | -35.0% | 25.04 | +2.6% | +3.2% | -1.1% | -1.0% | -1.0% | -0.2% | +0.1% | — |
| Feb 28, 2024 | AMC | -0.34 | -0.66 | -94.1% | 28.89 | -1.0% | -0.6% | +1.3% | -0.7% | -3.1% | -1.7% | -11.9% | — |
| Nov 2, 2023 | AMC | -0.64 | -0.57 | +10.9% | 28.39 | +5.3% | +5.7% | +3.4% | +5.7% | +4.8% | +0.3% | +11.7% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 29 | Stifel | Maintains | Buy → Buy | — | $94.00 | $93.85 | -0.2% | +0.2% | +3.5% | +2.7% | — | — |
| Apr 28 | Baird | Maintains | Outperform → Outperform | — | $92.48 | $93.34 | +0.9% | +1.6% | +1.9% | +5.2% | +4.4% | — |
| Apr 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $91.49 | $92.00 | +0.6% | +1.1% | +2.7% | +3.0% | +6.4% | +5.5% |
| Apr 21 | Citizens | Maintains | Market Outperform → Market Outperform | — | $95.71 | $95.08 | -0.7% | -2.5% | -1.5% | -3.9% | -4.4% | -3.4% |
| Mar 27 | TD Cowen | Maintains | Buy → Buy | — | $88.88 | $89.42 | +0.6% | -0.5% | -1.1% | +3.9% | +6.5% | +6.0% |
| Mar 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $88.51 | $88.77 | +0.3% | +1.0% | -0.7% | +1.9% | +0.4% | -0.1% |
| Mar 4 | Evercore ISI | Maintains | Outperform → Outperform | — | $87.80 | $89.16 | +1.5% | +6.0% | +0.0% | -1.7% | +1.1% | +3.6% |
| Feb 26 | Leerink Partners | Maintains | Outperform → Outperform | — | $108.62 | $96.53 | -11.1% | -15.1% | -15.0% | -17.1% | -19.2% | -14.3% |
| Feb 26 | TD Cowen | Maintains | Buy → Buy | — | $108.62 | $96.53 | -11.1% | -15.1% | -15.0% | -17.1% | -19.2% | -14.3% |
| Feb 26 | Citizens | Maintains | Market Outperform → Market Outperform | — | $108.62 | $96.53 | -11.1% | -15.1% | -15.0% | -17.1% | -19.2% | -14.3% |
Recent Filings
8-K
Mirum Pharmaceuticals, Inc. -- 8-K Filing
Mirum Pharmaceuticals' volixibat demonstrated acceptable safety in trials with expected gastrointestinal side effects and liver enzyme elevations, supporting potential regulatory progression for this IBAT inhibitor candidate.
May 4
8-K · 2.02
!! High
Travere Therapeutics, Inc. -- 8-K 2.02: Earnings Results
Travere Therapeutics reported quarterly earnings results; investors should review the attached press release for detailed financial performance metrics and guidance updates affecting TVTX stock valuation.
May 4
8-K
Mirum Pharmaceuticals, Inc. -- 8-K Filing
Mirum Pharmaceuticals will present Phase 2b AZURE-1 study results at EASL Congress in May 2026, providing investors key safety and efficacy data for its liver disease candidate.
Apr 27
8-K
Unknown — 8-K Filing
Mirum Pharmaceuticals completed a PIPE investment at $68.48/share with pre-funded warrants, providing capital for growth but diluting existing shareholders through new share issuance.
Apr 8
8-K
Mirum Pharmaceuticals, Inc. -- 8-K Filing
Mirum Pharmaceuticals reported $521 million in 2025 net product sales with guidance of $630-650 million for 2026, while advancing multiple clinical programs including volixibat, LIVMARLI, and brelovitug across PSC, cholestasis, and HDV indications.
Feb 25
Data updated apr 26, 2026 12:21pm
· Source: massive.com